Skip to main content
Premium Trial:

Request an Annual Quote

Geneyx Genomex Closes $6.5M Seed Financing Round

NEW YORK – Geneyx Genomex said Tuesday that it has closed a seed financing round worth approximately $6.5 million. Capri Ventures and Accenture Ventures led the round.

The firm, which is based in Herzliya, Israel, and Foster City, California, also said that it has joined Accenture Ventures' Project Spotlight, a program that helps connect software startups with major public companies.

Geneyx, which makes an artificial intelligence-driven genetic data analysis and interpretation platform to improve risk prediction and diagnostic yield, plans to use the funding to support global growth. The firm hopes to help its users achieve 90 percent diagnostic yield within the next two years with its analysis of whole-genome sequencing data.

"The opportunity for better diagnosis and treatments spanning the continuum of health from prediction to prognosis requires more sophisticated tools for collaboration across sectors of the healthcare and biomedical research ecosystem," Alex Pinchev, managing partner of Capri Ventures, said in a statement. "Geneyx's AI-based software solutions have the potential to transform healthcare by enhancing diagnostic and prognostic capabilities across patient populations and democratizing biomedical research."

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.